COMMUNIQUÉS West-GlobeNewswire

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
23/06/2025
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a [...]
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
23/06/2025
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
23/06/2025
New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on promising imaging data [...]
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
23/06/2025
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( [...]
New DoseSpot Analysis of 100,000 GLP-1 Prescriptions Finds That Patients Overpaid by $10.2M Collectively
23/06/2025
92 percent of prescriptions could have been filled at a lower price, with better information on pricing, dispensing options and manufacturer cost-savings programs BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- DoseSpot , [...]
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
23/06/2025
Basel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously [...]
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
23/06/2025
Ad hoc announcement pursuant to Art. 53 LR Idorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones and tiered royalty [...]
Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
23/06/2025
Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Recommandation fondée sur l’étude de phase 3 GMMG-HD7 [...]
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
23/06/2025
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment [...]
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
23/06/2025
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia [...]
SBC Medical Participated in 4 Investor Conferences in May and June 2025
23/06/2025
IRVINE, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, recently participated in [...]
Galapagos Appoints Aaron Cox as Chief Financial Officer
23/06/2025
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – [...]
Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors
23/06/2025
MUTTENZ, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose based peritoneal dialysis (PD) solution, today announced the [...]
AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer
23/06/2025
COMMUNIQUE DE PRESSE DE NOUVELLES DONNÉES ÉVALUÉES PAR DES PAIRS APPORTENT DES PREUVES SOLIDES DU POTENTIEL DU MASITINIB DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER GRÂCE À UN DOUBLE MÉCANISME D'AMÉLIORATION COGNITIVE [...]
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
23/06/2025
PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS [...]
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
23/06/2025
60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R 2 ) EO2463 plus R 2 was well tolerated in patients with follicular and marginal zone lymphoma EO2463 plus [...]
141,959 Orion Corporation A shares converted into B shares
23/06/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST 141,959 Orion Corporation A shares converted into B shares In accordance with [...]
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
23/06/2025
Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki 1 , 2 Fremanezumab demonstrated sustained effectiveness and a [...]
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
22/06/2025
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and [...]

Pages